ETFIQData as of Nov 19, 2026. · etfiq.com/funds/bout

BOUT Fact Sheet: CapForce IBD Breakout Opportunities ETF

Share
$36.63
close, Nov 20, 2026

Over the year to Nov 19, 2026, BOUT returned +4.8% in total and charged 0.80% a year.

1-year total return
+4.9%
to Nov 20, 2026
Expense ratio
0.80%
a year
Net flow, since Apr 2026
$0
monthly N-PORT basis to Jul 31, 2026

Growth of $10,000, 1 year

BOUT $10,483 +4.8% · Total return, distributions reinvested, Nov 19, 2025 to Nov 19, 2026.

Returns

WindowTotal return
1 month−13.9%
3 months−17.4%
Year to date+0.9%
1 year+4.9%
3 years+22.5%
5 years−0.1%

Total return, distributions reinvested, each window to Nov 20, 2026.

Ten largest positions

HoldingWeight
Enliven Therapeutics Inc7.26%
Bicara Therapeutics Inc7.04%
US Bancorp6.92%
Travere Therapeutics Inc6.84%
Waste Management Inc6.66%
Interface Inc6.26%
UBS Group AG6.13%
Goldman Sachs Group Inc4.71%
Bank of America Corp4.63%
PNC Financial Services Group I4.60%

BOUT top ten by weight, 61.0% of the fund, of its 25 equity positions, from the holdings filed for Jul 31, 2026.

Facts

Equity fund · First traded Sep 13, 2018 · Benchmark Its own holdings, as of Jul 31, 2026

Source: ETFIQ, from issuer disclosures, SEC filings and exchange prices. Returns from daily closes, distributions reinvested; each number is dated beside it, and every one is on the fund’s page.Cite as: ETFIQ, BOUT Fact Sheet: CapForce IBD Breakout Opportunities ETF. Data as of Nov 19, 2026. https://etfiq.com/funds/bout/fact-sheet/ETFIQ is an independent publisher. Not an issuer, broker or adviser. No recommendations. Printed from etfiq.com/funds/bout.